About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything? | Main | Reasons Not to Go to Grad School? »

January 8, 2010

Carl Icahn Going For Genzyme?

Email This Entry

Posted by Derek

That's what the folks at Fierce Biotech are saying. No doubt he sees an opening, given the company's current manufacturing troubles, and is planning to give them the same treatment he's been giving Biogen, just down the road. There are quite a few glossy condominium units available in Cambridge these days; maybe Icahn should buy one as a pied-a-terre if he's going to keep this stuff up.

But I hope that he doesn't. While I agree that it's worth having some corporate raiders around to keep companies on their toes, I think the nature of the biotech industry keeps things lively enough already. I tend to agree with Schumpeter's ideas about "creative destruction", but I worry that Icahn slips too often over to the "noncreative but lucrative" end of the destruction scale.

Comments (2) + TrackBacks (0) | Category: Business and Markets


1. anchor on January 8, 2010 10:00 AM writes...

Well said. We know form the past that as a board member, he can really create a havoc for the company as a whole, with little or no visibility to innocent outsiders. Genzyme is under lot of pressure (Pfizer, FDA) and at this point in time they do not Mr. Ichan. He is an opportunistic investor, who brings only harm.

Permalink to Comment

2. Hap on January 8, 2010 12:33 PM writes...

Viruses don't infect organisms because the organisms need viruses, but because the viruses need material and energy to survive and thrive - the effect on the organism (or its willingness to host them) is secondary to their well-being, and irrelevant to their decisions.

I think a book discussing the current pharma business environment should be called "Cannibalism for Fun and Profit".

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry